ITBMed is a biopharmaceutical company developing specific immunomodulatory biologics for transplantation, autoimmunity, neurodegenerative diseases, and gene therapy. The lead candidate drug siplizumab is a monoclonal antibody in clinical development, which has shown significant potential in transforming the life for organ transplant patients, by allowing the complete discontinuation of all immunosuppression treatment and restoration of a normal life.  

ITBMed also has a strong preclinical research and development profile, in collaboration with premier US and European universities, that has the potential to provide novel IP and break ground for new indications and treatments. 

Key facts 

  • Siplizumab – lead candidate drug, a humanized anti-CD2 directed monoclonal antibody, with unique mechanisms of action. Used in over 700 patients in Phase I/II trials.
  • Siplizumab is Orphan Drug Designated in both the US and Europe. 
  • Siplizumab has the potential to provide revolutionizing improvements in the treatment of transplant patients by:
    1. Allowing complete immunosuppression withdrawal long-term 
    2. Minimizing the toxicities of chronic standard-of-care immunosuppression use, including for example cancer, opportunistic infections, diabetes, hypertension, hyperlipidemia 
    3. Improving quality-of-life 
    4. Lowering healthcare costs 
  • Treatment potential in several areas of high clinical unmet need including organ transplantation, stem cell transplantation, autoimmunity, neurodegenerative diseases, and gene therapy. 
  • World-leading medical and scientific advisors. 
  • Board of Directors with long pharma, biotech, and medical expertise. 
  • Based in New York, USA and Stockholm, Sweden. 

Read our expanded access policy